Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human vaginal metagenome

ABSTRACT: Vaginal microbiome of Canadian HIV+ women

PROVIDER: PRJNA362575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5189080.fastq.gz	Fastqsanger.gz
	SRR5189090.fastq.gz	Fastqsanger.gz
	SRR5189100.fastq.gz	Fastqsanger.gz
	SRR5189110.fastq.gz	Fastqsanger.gz
	SRR5189120.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 54

Similar Datasets

human vaginal metagenome

Project description:Vaginal microbiome of Canadian women

| PRJNA278895 | ENA

human vaginal metagenome

Project description:Vaginal microbiome of pregnant Canadian women delivered preterm

| PRJNA403856 | ENA

Global Expression of Molecular Transporters in the Human Vaginal Tract

Project description:Pre-exposure chemoprophylaxis using antiretroviral agents is a promising strategy for the prevention of sexual HIV transmission in women. Molecular transporters in the human vaginal tract may play a pivotal role in determining drug disposition and, consequently, pharmacodynamic outcomes in these efforts. Little is known, however, on the expression of these transporters in vaginal tissues, representing a critical knowledge gap. Our study analyzed the genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women undergoing gynecologic surgeries. The genome-wide transcriptome in 44 vaginal tissue samples from 6 reproductive-age women (20-56 years old) undergoing gynecologic surgeries was measured.

2014-01-29 | E-GEOD-49892 | biostudies-arrayexpress

Human vaginal metagenome

Project description:Vaginal microbiome of South African women

| PRJNA767784 | ENA

human vaginal metagenome

Project description:Vaginal microbiome of healthy pregnant women

| PRJNA317763 | ENA

Global Expression of Molecular Transporters in the Human Vaginal Tract

2014-01-29 | GSE49892 | GEO

Results of the phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel

Project description:Griffithsin (GRFT) is an anti-viral lectin with potent anti-HIV activity. GRFT’s preclinical safety, lack of systemic absorption after topical administration, and lack of cross-resistance with existing products prompted its development for topical HIV pre-exposure prophylaxis. We evaluated safety, pharmacokinetics and pharmacodynamics of PC-6500 (0.1% GRFT in a carrageenan (CG) gel) in healthy, HIV-negative, non-pregnant women following once daily vaginal gel administration for 14 days. No significant adverse events, histopathological changes in cervico-vaginal mucosa, or anti-drug (GRFT) antibodies were detected. No cervicovaginal proinflammatory responses and no changes in the ectocervical transcriptome were evident. Vaginal microbiome remained largely unchanged. Reduced abundance of vaginosis-associated bacteria and decreased levels of proinflammatory chemokines (CXCL8 and CCL20) were observed. GRFT was not detected in plasma. GRFT and GRFT/CG in CVLs dose-dependently inhibited HIV and HPV, respectively, in vitro. The data suggest GRFT/CG is a promising on-demand multipurpose prevention product that warrants further investigation.

2021-10-04 | GSE141478 | GEO

human vaginal metagenome

Project description:vaginal microbiome of pregnant women with penicillin allergy

| PRJNA595036 | ENA

The Dynamics of the Vaginal Microbiome During Infertility Therapy with In Vitro Fertilization-Embryo Transfer

Project description:Clinical treatment protocols for infertility with in vitro fertilization-embryo transfer (IVF-ET) provide a unique opportunity to assess the human vaginal microbiome in defined hormonal milieu. Herein, we have investigated the association of circulating ovarian-derived estradiol (E2) and progesterone (P4) concentrations to the vaginal microbiome. Thirty IVF-ET patients were enrolled in this study, after informed consent. Blood was drawn at four time points during the IVF-ET procedure. In addition, if a pregnancy resulted, blood was drawn at 4-to-6 weeks of gestation. The serum concentrations of E2 and P4 were measured. Vaginal swabs were obtained in different hormonal milieu. Two independent genome-based technologies (and the second assayed in two different ways) were employed to identify the vaginal microbes. The vaginal microbiome underwent a transition with a decrease in E2 (and/or a decrease in P4). Novel bacteria were found in the vagina of 33% of the women undergoing IVF-ET. Our approach has enabled the discovery of novel, previously unidentified bacterial species in the human vagina in different hormonal milieu. While the relationship of hormone concentration and vaginal microbes was found to be complex, the data support a shift in the microbiome of the human vagina during IVF-ET therapy using standard protocols. The data also set the foundation for further studies examining correlations between IVF-ET outcome and the vaginal microbiome within a larger study population.

2011-10-24 | E-MEXP-2958 | biostudies-arrayexpress

human vaginal metagenome

Project description:Key Vaginal Bacteria Associated with Increased Risk of HIV Acquisition in African Women

| PRJNA420364 | ENA